Literature DB >> 36040602

Endobronchial Gene Delivery for Pulmonary Hypertension in a Large Animal Model.

Olympia Bikou1, Kiyotake Ishikawa2.   

Abstract

Pulmonary hypertension (PH) is a devastating disease with high morbidity and mortality. Despite significant progress in the pharmacotherapy, current treatments only ameliorate the symptoms and cannot heal PH. Gene therapy may target the roots of the disease and holds evident promise. The current bottleneck for lung gene therapy is the delivery method. The requirements for the delivery mode are efficiency, safety, and the ability to target the anatomical site of interest, while avoiding off-target effects. Aerosolized gene delivery has been used in several studies and proven to be an efficient mode of administration for lung gene therapy. In this chapter, we describe a protocol of endobronchial aerosolization for PH gene therapy in a large animal model. Testing of a gene therapy in large animals is essential before clinical testing, since the lung anatomy and (patho)physiology differ immensely between humans and rodents, where most of the proof-of-concept studies are tested. The gene delivery vector is being aerosolized in the peripheral bronchi using a sprayer inserted through a flexible bronchoscope. This delivery mode results in efficient lung uptake and less off-target distribution relative to other airway delivery methods.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adeno-associated virus (AAV); Aerosolization; Endobronchial delivery; Flexible bronchoscope; Lung gene therapy; Pulmonary hypertension; Sprayer

Mesh:

Year:  2022        PMID: 36040602     DOI: 10.1007/978-1-0716-2707-5_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  Coarse spray delivery to a localized region of the pulmonary airways for gene therapy.

Authors:  D C Cipolla; I Gonda; S Shak; I Kovesdi; R Crystal; T D Sweeney
Journal:  Hum Gene Ther       Date:  2000-01-20       Impact factor: 5.695

2.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.

Authors:  Marius M Hoeper; Tilmann Kramer; Zixuan Pan; Christina A Eichstaedt; Jens Spiesshoefer; Nicola Benjamin; Karen M Olsson; Katrin Meyer; Carmine Dario Vizza; Anton Vonk-Noordegraaf; Oliver Distler; Christian Opitz; J Simon R Gibbs; Marion Delcroix; H Ardeschir Ghofrani; Doerte Huscher; David Pittrow; Stephan Rosenkranz; Ekkehard Grünig
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 3.  Pulmonary arterial hypertension: challenges in translational research and a vision for change.

Authors:  Gopinath Sutendra; Evangelos D Michelakis
Journal:  Sci Transl Med       Date:  2013-10-23       Impact factor: 17.956

4.  Modeling Pulmonary Hypertension: A Pig Model of Postcapillary Pulmonary Hypertension.

Authors:  Olympia Bikou; Kiyotake Ishikawa; Kenneth M Fish; Iratxe Zarragoikoetxea; Roger J Hajjar; Jaume Aguero
Journal:  Methods Mol Biol       Date:  2018

5.  Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

Authors:  Vallerie V McLaughlin; Marius M Hoeper; Richard N Channick; Kelly M Chin; Marion Delcroix; Sean Gaine; Hossein-Ardeschir Ghofrani; Pavel Jansa; Irene M Lang; Sanjay Mehta; Tomás Pulido; B K S Sastry; Gérald Simonneau; Olivier Sitbon; Rogério Souza; Adam Torbicki; Victor F Tapson; Loïc Perchenet; Ralph Preiss; Pierre Verweij; Lewis J Rubin; Nazzareno Galiè
Journal:  J Am Coll Cardiol       Date:  2018-02-20       Impact factor: 24.094

6.  ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.

Authors:  Vallerie V McLaughlin; Stephen L Archer; David B Badesch; Robyn J Barst; Harrison W Farber; Jonathan R Lindner; Michael A Mathier; Michael D McGoon; Myung H Park; Robert S Rosenson; Lewis J Rubin; Victor F Tapson; John Varga
Journal:  J Am Coll Cardiol       Date:  2009-04-28       Impact factor: 24.094

7.  Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.

Authors:  Jaume Aguero; Kiyotake Ishikawa; Lahouaria Hadri; Carlos G Santos-Gallego; Kenneth M Fish; Erik Kohlbrenner; Nadjib Hammoudi; Changwon Kho; Ahyoung Lee; Borja Ibáñez; Ana García-Alvarez; Krisztina Zsebo; Bradley A Maron; Maria Plataki; Valentin Fuster; Jane A Leopold; Roger J Hajjar
Journal:  J Am Coll Cardiol       Date:  2016-05-03       Impact factor: 24.094

8.  Safety and long-term efficacy of AAV1.SERCA2a using nebulizer delivery in a pig model of pulmonary hypertension.

Authors:  Shin Watanabe; Kiyotake Ishikawa; Maria Plataki; Olympia Bikou; Erik Kohlbrenner; Jaume Aguero; Lahouaria Hadri; Iratxe Zarragoikoetxea; Kenneth Fish; Jane A Leopold; Roger J Hajjar
Journal:  Pulm Circ       Date:  2018-08-21       Impact factor: 3.017

9.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 10.  Genetic Delivery and Gene Therapy in Pulmonary Hypertension.

Authors:  Nabham Rai; Mazen Shihan; Werner Seeger; Ralph T Schermuly; Tatyana Novoyatleva
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.